Merck Signs On For Neuromed’s Chronic Pain Agent
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck could pay up to $450 mil. for the class of oral N-type calcium channel blockers.
You may also be interested in...
Merck, Neuromed Discontinue N-Type Calcium Channel Blocker For Pain
Companies will continue a joint research effort to deliver a “best in class” candidate, Neuromed CEO Gallen tells “The Pink Sheet” DAILY.
Merck, Neuromed Discontinue N-Type Calcium Channel Blocker For Pain
Companies will continue a joint research effort to deliver a “best in class” candidate, Neuromed CEO Gallen tells “The Pink Sheet” DAILY.
Neuromed Deal With Alza Will Accelerate Commercialization Strategy
Neuromed will develop a sales force to launch OROS hydromorphone in the U.S. in 2009 under a collaboration with the J&J subsidiary.